The 10K filing shows that consolidated R&D costs increased by $0.7 million, or 1.0%, in 2024, as compared to 2023. This demonstrates a commitment to innovation and new product development.

The filing indicates that Net cash used in investing activities increased by $10.0 million in 2024, due to an increase in capital expenditures for additional manufacturing capacity to meet future customer demand.

The 10K filing states that the company has operations based in Israel that conduct research and development activities and manufacture certain components for devices and that the company continues to monitor the impact of the conflict in Israel and surrounding areas on operations and those of suppliers.

The 10K filing shows that consolidated SG&A costs decreased by $14.9 million, or 4.2%, in 2024, including a favorable foreign currency translation impact of $0.5 million. This suggests improved efficiency in administrative and selling functions.

The 10K filing states that the company recorded expense to restructuring and other charges of $2.1 million, which includes $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries.

The 10K filing states that the company must adjust its production capacity in accordance with customer demand changes and remain focused on increasing capacity at various facilities through its capital strategy.

The 10K filing mentions that General global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, may result in unfavorable conditions.

The 10K filing states that Our systems and networks, as well as those of our customers, suppliers, service providers, and banks, have and may in the future become the target of cyberattacks or information security breaches which, in turn, could result in the unauthorized release and misuse of confidential or proprietary information about our company, our employees or our customers, as well as disrupt our operations or damage our facilities or those of third parties.

The 10K filing mentions that Our international operations and our ability to implement our overall business strategy (including our plan to continue expanding into emerging and/or faster-growing markets outside of the U.S.) are subject to risks and uncertainties that can vary by country, and include: transportation delays and interruptions; political and economic instability and disruptions; imposition of duties and tariffs; import and export controls; the risks of divergent business expectations or cultural incompatibility inherent in establishing and maintaining operations in foreign countries; difficulties in staffing and managing multi-national operations; labor strikes and/or disputes; and potentially adverse tax consequences.

The 10K filing states that we face continued pricing pressure from our customers and competitors and that if we are unable to resist or offset the effects of continued pricing pressure through our value-added services, improved operating efficiencies and reduced expenditures, or if we have to reduce our prices, our sales and profitability may suffer.

The 10K filing mentions that consolidation within the industries we serve could exert additional pressure on the prices of our products.

The 10K filing states that The medical technology industry is subject to rapid technological changes, and we face significant competition across our product lines and in each market in which our products are sold.

The 10K filing states that these types of extreme weather events have and may continue to adversely impact us, raw material availability, our suppliers, our customers and their ability to purchase our products and our ability to timely manufacture and transport our products.

The 10K filing mentions that The functioning of our manufacturing and distribution assets and systems could be disrupted for reasons either within or beyond our control, including, without limitation: extreme weather, water scarcity and other longer-term climatic changes; natural or man-made disasters; pandemic; war; accidental damage; disruption to the supply of material or services; product quality and safety issues; power outages; systems failure; workforce actions; or environmental matters.

The 10K filing states that a reduction or interruption in supply, or an inability to secure alternative sources of raw materials or components, could have a material adverse effect on our business and/or results of operations.

The 10K filing states that we seek to differentiate ourselves by leveraging our global capabilities and reputation and by employing new technologies such as high-speed automated assembly, insert-molding, multi-shot precision molding, and expertise with multiple-piece closure systems.

The 10K filing mentions that our quality control, regulatory and laboratory testing capabilities are used to ensure compliance with applicable manufacturing and regulatory standards for primary and secondary pharmaceutical packaging components and drug delivery systems.

The 10K filing states that The process of obtaining and maintaining FDA and other required regulatory approvals is expensive and time-consuming.

The 10K filing indicates that During the year ended December 31, 2024, we purchased 1,583,032 shares of our common stock under the program at a cost of $560.9 million, or an average price of $354.30 per share.

The 10K filing indicates that Dividends declared ($0.78 per share) (57.8).

The 10K filing states that Our sources of liquidity include our multi-currency revolving credit facility and that At December 31, 2024, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million.

The 10K filing states that West has been committed to ESG topics for many years and that During 2024, we continued to increase internal and external awareness of our ESG commitment by expanding our education and communication regarding our ESG program and initiatives and more closely integrating ESG considerations into our business processes.

The 10K filing mentions that Our ESG program includes a senior-level cross-functional ESG team which has been working with executive leadership, our board and other stakeholders to enhance our ESG framework and ensure alignment with our corporate mission, vision and values.

The 10K filing states that Our long-term strategic priorities include focus on talent attraction, retention and engagement; a climate and greenhouse gas ( GHG ) reduction strategy that incorporates renewable energy and reduced absolute and intensity emissions; developing a more sustainable and responsible supply chain; research and development that focuses on issues of sustainability including secondary packaging, beneficial reuse and recyclability; and, reduction of waste and water in our operational processes.

The 10K filing states that We have operations based in Israel that conduct research and development activities and manufacture certain components for our devices.

The 10K filing mentions that We are subject to stringent and changing obligations related to data privacy and security and that Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm and other adverse business consequences.

The 10K filing states that There is continuing concern from members of the scientific community and the general public that emissions of GHG and other activities have or will cause significant changes in weather patterns and increase the frequency or severity of extreme weather events, including droughts, hurricanes, wildfires and flooding.